VACCINE

• US 20170042997A1
• Filed: 04/29/2015
• Published: 02/16/2017
• Est. Priority Date: 04/29/2014
• Status: Abandoned Application

• Current Assignee: Medizinische Hochschule Hannover
• Original Assignee: Medizinische Hochschule Hannover
• Inventors: Wirth, Thomas
• Application Number:
  US15/306,339
• Publication Number:
  US 20170042997A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/6056 Antibodies
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/55 Lung
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/15 Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/4615 Dendritic cells
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/4634 Antigenic peptides; polypeptides
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2878 : against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/75 : Agonist effect on antigen

Abstract

The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g. be an autoantigen like a malignant antigen, i.e. a tumour-specific antigen. The pharmaceutical combination of compositions comprises a first composition and a second composition, wherein the second composition is for administration to recipient subsequent to the administration of the first composition, e.g. 2 to 10 days after the first composition. The pharmaceutical combination of compositions has the advantage of raising an effective antigen-specific T-cell response against cells bearing a target antigen that can be a malignant autoantigen, e.g. for raising an antigen-specific T-cell response against cells bearing a tumour-antigen. A further advantage is that the pharmaceutical combination of compositions can raise an antigen-specific T-cell response within a comparatively short time.

Claims

1. Pharmaceutical combination of compositions for use in medical treatment, the combination comprising a first composition comprising dendritic cells (DC) which are immunologically compatible with a recipient and which are associated with a target antigen and a second composition comprising at least a portion of the target antigen in soluble form and a co-stimulatory antibody effective for activating T-cells and/or the dendritic cells (DC), wherein the second composition is for administration at a time at least 1 day subsequent to administration of the first composition.

2. Pharmaceutical combination according to claim 1, wherein the dendritic cells (DC) are associated with the target antigen by being contacted with the target antigen or by being contacted with a nucleic acid sequence encoding the antigen.

13. Pharmaceutical combination according to claim 2, wherein the dendritic cells (DC) following in vitro contact with the target antigen by being contacted with the target antigen or by being contacted with a nucleic acid sequence encoding the antigen are separated from the medium containing the target antigen or nucleic acid sequence encoding the antigen and are expanded in number by cultivation in cell culture medium.

16. Pharmaceutical combination according to claim 1, wherein the second composition further contains a non-specific TLR3 agonist, TLR7 agonist, TLR4 agonist, TLR9 agonist or combinations of at least two of these.

17. Pharmaceutical combination according to claim 1, wherein the co-stimulatory antibody effective for activating professional antigen presenting cells (APC) is selected from the group consisting of anti-CD137 antibody, an anti-CD40 antibody, an anti-OX40 antibody, anti-ICOS antibody, an anti-CD27 antibody, an anti-CD28 antibody, an anti-GITR antibody, specifically anti-human GITR/AITR antibody, an anti-HVEM antibody, an anti-TIM1 antibody, an anti-TIM3 antibody, and mixtures of at least two of these.

18. Pharmaceutical combination according to claim 1, wherein the second composition further comprises a non-specific TLR3 agonist that is Poly(I:

C) and/or PolyICLC or a homologue thereof.

19. Pharmaceutical combination according to claim 1, wherein the first composition is free from an adjuvant.

3. Pharmaceutical combination of compositions for use in medical treatment, the combination comprising a first composition comprising an antibody specific for a surface receptor of a dendritic cell (DC) coupled to a target antigen and a second composition comprising at least a portion of the target antigen in soluble form and a co-stimulatory antibody effective for activating T-cells and/or dendritic cells (DC), wherein the second composition is provided for administration at a time at least 1 day subsequent to administration of the first composition.

4. Pharmaceutical combination according to claim 3, wherein the antibody specific for a surface receptor of a dendritic cell (DC) is an anti-DEC205 antibody and/or an anti-DCIR antibody.

5. Pharmaceutical combination according to claim 3, wherein the medical treatment is the treatment of tumour, of viral infections or of infections by intracellular bacteria.

6. Pharmaceutical combination according to claim 3, wherein the second composition further contains a non-specific TLR3 agonist, TLR7 agonist, TLR4 agonist, TLR9 agonist or combinations of at least two of these.

7. Pharmaceutical combination according to claim 3, wherein the co-stimulatory antibody effective for activating professional antigen presenting cells (APC) is selected from the group consisting of anti-CD137 antibody, an anti-CD40 antibody, an anti-OX40 antibody, anti-ICOS antibody, an anti-CD27 antibody, an anti-CD28 antibody, an anti-GITR antibody, specifically anti-human GITR/AITR antibody, an anti-HVEM antibody, an anti-TIM1 antibody, an anti-TIM3 antibody, and mixtures of at least two of these.

8. Pharmaceutical combination according to claim 3, wherein the non-specific TLR3 agonist is Poly(I:

C) and/or PolyICLC or a homologue thereof.

9. Pharmaceutical combination according to claim 3, wherein the medical treatment is for raising in a recipient a cellular immune response specifically directed against cells of the recipient bearing the target antigen.

10. Pharmaceutical combination according to claim 3, wherein the first composition is free from an adjuvant.

11. Pharmaceutical combination according to claim 5, wherein the tumour is selected from the group comprising or consisting of hematological malignancies, Hodgkin and non-Hodgkin lymphomas, leukemias, especially acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, monocytic leukemia, myelomas, myeloproliferative diseases, myelodysplastic syndromes and solid cancers, especially originating from brain, head and neck, lung, pleura, heart, liver, kidney, colon, pancreas, stomach, gut, urinary tract, prostate, uterus, ovaries, breast, skin, testes, larynx and sarcoma.

12. Pharmaceutical combination according to claim 5, wherein the tumour antigen is selected from the group consisting of tumour antigens, tumour homogenate or tumour lysate.

14. Pharmaceutical combination according to claim 3, wherein the medical treatment comprises the generation of CD8+ T-cells which are specific for the target antigen and/or the generation of CD4+ T-cells which are specific for the target antigen.

15. Pharmaceutical combination according to claim 3, wherein the medical treatment generates activated CD8+ T-cells having specificity for autologous cells comprising the antigen.